IMAZODAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H12N4O
Molecular Weight	240.2606
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1CCC(=NN1)C2=CC=C(C=C2)N3C=CN=C3

InChI

InChIKey=VXMYWVMXSWJFCV-UHFFFAOYSA-N

InChI=1S/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1715125 | https://adisinsight.springer.com/drugs/800000379

Imazodan, a phosphodiesterase III inhibitor was developed by Parke-Davis to treat heart failure and ischemic heart disorders. However, the study of this drug was discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 3 60 Target ID: CHEMBL2094125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2559580 \| https://medkoo.com/products/10206	Inhibitor 8297

PubMed

Title	Date	PubMed
Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties.	1993 Jun	7687727
Mechanisms of leptin secretion from white adipocytes.	2002 Jul	12055093
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.	2006 Aug	16928983
Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex.	2008 Jul 15	18570382

Sample Use Guides

In Vivo Use Guide

Patients were randomized to placebo or 2, 5 or 10 mg of imazodan administered twice daily.

Route of Administration: Oral

Name

Type

Language

IMAZODAN

Official Name

English

imazodan [INN]

Common Name

English

IMAZODAN [MART.]

Common Name

English

4,5-DIHYDRO-6-(P-IMIDAZOL-1-YLPHENYL)-3(2H)-PYRIDAZINONE

Common Name

English

3(2H)-PYRIDAZINONE, 4,5-DIHYDRO-6-(4-(1H-IMIDAZOL-1-YL)PHENYL)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744